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Background: Though percutaneous coronary intervention with the XIENCE V ever-
olimus-eluting stent (EES, Abbott Vascular, Santa Clara, CA) for native coronary artery
disease has favorable results compared to ﬁrst generation drug-eluting stents, outcomes
with EES for the treatment of in-stent restenosis (ISR) are unknown. The objective of this
study is to evaluate the safety and efﬁcacy of XIENCE V for the treatment of ISR.
Methods: XIENCE V USA is a prospective observational multicenter registry eval-
uating clinical outcomes in patients who received treatment with EES. In this study,
we present the 1-year clinical outcomes in patients who received EES for the treatment
of ISR and non-ISR in this registry. The primary outcome was the composite of target
lesion failure (deﬁned as cardiac death, target vessel myocardial infarction, or target
lesion revascularization). Secondary outcomes were myocardial infarction, target
lesion revascularization, and stent thrombosis.
Results: In this registry 383 patients (6411 years old; 68.4% male) received
revascularization for single-vessel ISR and 4832 patients (6411 years old; 69.0%
male) received revascularization for non-ISR lesions. At 1 year, the rate of clinical
adverse events (Table) was higher in the ISR group compared the non-ISR group,
however, these differences ceased to exist when case-control matched patients in the
non-ISR group were studied.
Conclusions: The treatment of ISR with EES appears to be safe and efﬁcacious at
1-year follow-up. Compared to the non-ISR group, the rate of target lesion failure was
much higher indicating a higher risk proﬁle of these patients. However, these
differences ceased to exist with case controlled matching.Table. Clinical outcomes at 1 year.
ISR Group (N=383)
Non-ISR Group
(N=4,832)
Case-Matched Non-
ISR Group (N=317)
Target Lesion Failure
(ARC MI)
12.5% 7.0% 10.5%
Myocardial Infarction
(ARC)
7.2% 5.8% 7.1%
Target Lesion
Revascularization
10.3% 2.9% 6.8%
Stent thrombosis
(ARC Deﬁnite)
1.7% 0.2% 0.7%TCT-456
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Background: Pathological studies have revealed atherosclerotic neointima (AN) after
stent implantation. However, the risk factor of neoatherosclerosis and its impact on
future clinical events remain unclear.
Methods: From the Kobe university OCT database, 137 consecutive patients (253
stents) who underwent OCT examination at >1 year after bare metal or ﬁrst-gener-
ation drug-eluting stent implantation were enrolled. We assessed AN (neointima
containing a diffuse border, signal-poor region with invisible struts underneath) by
follow-up OCT and compared major adverse cardiovascular event (MACE: death,
recurrent myocardial infarction and target lesion revascularization (TLR)) rate
between +AN and –AN group.
Results: 38 patients had AN at follow-up OCT, who had higher LDL-cholesterol and
high sensitivity CRP (hs-CRP) level. In multivariate logistic analysis, LDL cholesterol
and hs-CRP were the independent predictors of the presence of AN (OR 1.025
(P¼0.011), OR 1.016 (P¼0.045), respectively). The rate of MACE were signiﬁcantly
higher in +AN than in -AN for an average follow-up of 58 months after stenting. AfterB140 JACC Vol 62/18/Suppl B j October 27–November 1, 20multivariate cox hazard analysis, the presence of AN remained an independent risk
factor of MACE (HR 2.345, 95% CI 1.010-5.440, P¼0.047).Conclusions: Increased LDL-cholesterol and hs-CRP level may be risk factors for AN
progression in patients treated with coronary stents. In this study, the presence of AN
assessed by OCT were independently associated with MACE at >1 year after stent
placement, suggesting a need for careful clinical follow-up of patients with AN.
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Background: The clinical presentation of bare metal in-stent restenosis (ISR) is re-
ported to be associated with high rates of morbidity, including myocardial infarction
(MI). This study aimed to compare the clinical presentation and outcomes between
patients treated with 1st- versus 2nd-generation drug-eluting stents (DES) and pre-
sented with ISR on admission.
Methods: The study identiﬁed ﬁrst episode 1st or 2nd-generation DES ISR patients
who underwent re-intervention. The clinical presentation at admission was classiﬁed
as non acute (asymptomatic or stable angina) or acute (unstable angina, Canadian
Cardiovascular Society (CCS) III or IV and MI). We compared the 1st- vs. 2nd-gen
DES ISR clinical presentation and the rates of major adverse cardiac events (MACE)
as a composite of death, Q-wave MI and target lesion revascularization at 6 months.
Results: Overall, 709 patients with 1095 DES ISR lesions (1st-gen DES n¼526; 2nd-
gen DES n¼113) were selected. The mean age was 65  10 years and diabetics
comprised 49%. Clinical presentation included asymptomatic/stable angina in 29%,
unstable angina in 62% and MI in 8%. Patients with 2nd-generation DES ISR were
less likely to present as MI(13% vs. 5%; p¼0.05) and with severe symptoms (73% vs.
49%, p<0.01) as compared to 1st-gen DES. The incidence of MACE in the 1st- and
2nd-gen DES at 6 months was 8% and 9%, respectively (p¼1.0).
Conclusions: 2nd-generation DES ISR clinical presentation appears to be more
benign with less frequency of MI and CCS III or IV symptoms compared to 1st-
generation DES. The rates of MACE were similar at 6 months.TCT-458
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Background: Clinical studies demonstrated the effectiveness and safety of drug-coated
balloon (DCB) in various clinical scenarios and support the use of paclitaxel-coated
balloon for the treatment of in-stent restenosis, of small coronary arteries and bifurcation
lesions.A fewsmall scale studies have reported excellent immediate and short term results
of DCB use compared to non-coated balloon for de-novo lesions. Initial angiographic13 j TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis
